In 2005, GLP-1 drugs were first approved to treat type 2 diabetes. Today, the glucagon-like peptide-1 drugs have transformed not just diabetes treatment but weight-loss management and the healthcare industry as a whole. Ozempic, Wegovy, Mou
In 2005, GLP-1 drugs were first approved to treat type 2 diabetes.
Today, the glucagon-like peptide-1 drugs have transformed not just diabetes treatment but weight-loss management and the healthcare industry as a whole.
Ozempic, Wegovy, Mounjaro and Zepbound among others have become household names with roughly 11% of Americans taking one.
Women in midlife are driving the GLP-1 surge and usage is highest among adults 50-64, with one in five reporting use.
And as consumer demand soars, drugmakers are looking toward the future, prepping the next generation of weight management treatments.
Your Peptide Starter Pack Enter "Reta." Short for Retatrutide, the experimental drug from Eli Lilly is already being positioned online as the next big thing in weight loss.
It has inspired before-and-after videos, dosing diaries, side-effect reports and an entire ecosystem of people discussing where to buy it.
There is just one rather enormous catch: Retatrutide is not approved by the U.S.
Food and Drug Administration FDA or commercially available anywhere in the world.
What Is Retatrutide — And Is It Really a 'GLP-3'?
Retatrutide is an investigational once-weekly injection designed to activate three hormone receptors: GLP-1, GIP glucose-dependent insulinotropic polypeptide and glucagon.
Semaglutide, sold as Wegovy for weight loss and Ozempic for type 2 diabetes, targets GLP-1.
Tirzepatide, sold as Zepbound and Mounjaro, activates GLP-1 and GIP glucose-dependent insulinotropic polypeptide .
Retatrutide adds glucagon, which may increase energy expenditure and help the body burn fat.
That has earned it the social media nickname "GLP-3," but the term is scientifically inaccurate.
Retatrutide does not activate three GLP-1 receptors.
It is more accurately described as a triple hormone receptor agonist or "triple G" agonist.
"GLP-1 reduces appetite, GIP appears to complement those effects, and glucagon may increase energy expenditure," explains licensed pharmacist Eddie Khoriaty, co-founder of GlowPure.
"The idea is to influence several aspects of metabolism at the same time." Why Reta Is Generating So Much Hype The early numbers help explain the excitement.
In company-reported Phase 3 results, participants without diabetes who received the highest dose lost an average of 28.3% of their body weight after 80 weeks.
Comparatively, patients on a tirzepatide, such as Mounjaro or Zepbound, experience ~20% to 21% weight loss over roughly 72 weeks, while patients on semaglutide, such as Ozempic or Wegovy, lose ~15% of weight over roughly 68 weeks.
Among a subset of participants with a starting body mass index BMI of at least 35 who completed an extension study, average weight loss reached 30.3% after two years.
So, patients who started at 200 pounds lost on average 61 pounds, ending up at 139 pounds by the end of the study.
Retatrutide has produced "promising effects for weight management that we have not seen to this degree with any of the previous incretin mimetics," says Dr.
Holly Lofton, director of NYU Langone's Medical Weight Management Program.
"However, it is not for everyone." The potential impact is significant.
"Those are numbers we once believed only possible with bariatric surgery," says Dr.
Carol Eisenstat, a board-certified physician and founder of Line Eraser MD.
"If its safety profile checks out, it dramatically redefines the upper limit of pharmacotherapy." But "if" is doing important work in that sentence.
The results are topline data reported by Lilly, retatrutide has not yet been compared head-to-head with earlier drugs in a completed clinical trial and questions about its long-term safety and effectiveness remain.
Reta Is Already Everywhere Online Retatrutide has nevertheless become a full-blown social media phenomenon.
On TikTok, Instagram and YouTube, users document alleged reta journeys, discuss dosages and direct followers toward suppliers.
Recent reporting has found young people promoting and injecting purported Retatrutide on TikTok, despite its investigational status.
Reddit has nearly 30 communities devoted specifically to Reta, including country-specific forums, groups for men and women and communities focused on results or trial data.
At the time Flow Space reviewed them, the largest, r/Retatrutide, showed 189,000 weekly visitors and 12,000 weekly contributors.
The posts can make Reta appear to be simply another medication people are accessing ahead of the official launch.
It is not.
The 'Reta' Sold Online Is Not the Trial Drug Dr.
Mike Ellis, an internal medicine physician and medical director of Keep Glowing Medical Spa, says purported Reta is being sold through "research peptide" websites and overseas suppliers, often as a powder labeled "for research use only" or "not for human consumption." Even if a product is marketed as retatrutide, that does not mean it contains the investigational medication manufactured and monitored by Lilly.
Ellis cautions, "You do not know what you are actually getting in your medication vial, what the concentration of the medication is or if the product is sterile and safe to inject," he says.
Regardless, FOMO is real, and some consumers are nevertheless mixing these powders into liquids themselves and injecting them.
The FDA says retatrutide cannot legally be used in compounding and warns that products sold online may contain too much, too little or none of the advertised ingredient — along with potentially harmful contaminants.
Eisenstat insists that "the drug being tested in the trial is not the same product as what is in the vial someone purchased online." Much like GLP-1s, the authentic Retatrutide has been shown to produce significant side effects under clinical supervision.
At the highest dose, 42.4% of trial participants experienced nausea, 32% had diarrhea, 26.1% reported constipation and 25.3% experienced vomiting.
About 11% stopped treatment because of adverse events.
While Retatrutide shows enormous promise, the products circulating online are not the same drug being tested in clinical trials — and consumers should know the difference.
Until Reta is approved and regulated buyers should beware.
Viral doesn't mean verified.
View comments About our ads
Peptides referenced: Semaglutide, Tirzepatide, Retatrutide, Glucagon, GLP-1.
Related reading: Everyone Wants 'Reta,' but the Real Retatrutide Isn't Available Yet, Retatrutide Nears Filing Amid Eli Lilly BLA Dispute, Could GLP-1 Drugs Lower Heart Attack Risk?, UK Inquest Exposes Diagnostic Trap: Mounjaro Side Effects Mimic Bowel Perforation.